Superior vena cava(SVC)syndrome is a syndrome caused by impaired venous return due to stenosis of the SVC. Most of such cases are due to tumors(non-small cell lungcancer, small cell lungcancer, malignant lymphoma, etc), and the most common cause of SVC syndrome is lungcancer. Symptoms of SVC syndrome are caused by external compression of the SVC, direct invasion, internal thrombus or embolization. Increased venous pressure results in objective findings including edema of the face and neck, edema of the upper limbs, superficial precordial vein distension due to collateral circulation, and hoarseness and subjective symptoms includingcoug h, dyspnea, syncope, headache, and dizziness. SVC syndrome impair the patient's quality of life(QOL). Although there are cases of spontaneous remission, SVC syndrome is recognized as one of the oncologic emergencies because brain and laryngeal edema can be fatal and urgent care should be provided. Therapeutic modalities include radiotherapy, chemotherapy, stent placement and surgery. Treatment should be determined comprehensively based on the severity, histological type, standard therapy for the histological type and its sensitivity. It is necessary to make a definitive histopathological diagnosis as soon as possible and to cooperate with other departments to promptly select the most appropriate treatment.In Japan, clinically, a decade has passed since KRAS exon 2 hotspot mutations could be measured as a companion diagnostic agent of an anti-epidermal growth factor receptor antibody to treat unresectable advanced colorectal cancer. Till now, not only KRAS exon 2, but also KRAS exon 3, 4 and NRAS exon 2-4 mutation, and BRAF mutation(V600E)are approved as insurance as a companion diagnostics tool. In addition to those somatic mutations observed in Ras-Raf signal cascade, the measurement of microsatellite instability status is also approved as a companion diagnostic to anti-programmed death-1 receptor antibodies. Since these somatic mutational profiles in colorectal cancer cells are measured to determine the propriety of administration of a particular medicine, the results must be appropriately reflected in therapy for each patient. In this review, I will summarize the feature of clinical characteristics belonging to each somatic mutational profile commonly observed in colorectal cancer, and discuss howsuch somatic mutational profiles including RAS, BRAF mutation, and microsatellite instability status bring us to a newera of colorectal cancer.Introduction Penile prosthesis implant is a safe and effective option in erectile dysfunction patients, being implant procedures safe with a low risk of infection. However, when infection occurs, it represents a concrete problem for both surgeon and patient. Methods This is a comprehensive review of all issues relating to prosthesis infection, including causes and risk factors, methods of prevention, and management. We analyzed all preoperative and perioperative factors, which can play a role in infection of the device. Results Infection of penile prosthesis implant is hard to manage and correct. While the incidence of infection following first implant is up to 3%, in cases of re-implant surgery, the rate can reach as high as 18%. Many articles were found addressing prevention and treatment of penile prosthesis infection, and many analyzed all relevant pre- and perioperative factors associated with penile prosthesis implant. Although such factors have been well studied, there is no clear consensus worldwide on certain topics. Conclusions Penile prosthesis implant is a safe and effective option. https://www.selleckchem.com/products/fasoracetam-ns-105.html Despite infection is a rare event, surgeons should follow strictly pre-, intra- and postoperative recommendations in order to reduce the risk of device's infection. An appropriate antibiotic therapy should be tailored on patient's characteristics and pathogens isolated.Introduction Above-label doses of somatostatin analogs (SSAs) are increasingly utilized in the management of inoperable/metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), progressing on standard 4-weekly regimens. Objective To evaluate the antiproliferative effect of 3-weekly SSA administration in a retrospective GEP-NETs cohort. Methods Patients with advanced GEP-NETs, treated with long acting release (LAR) octreotide 30mg or lanreotide Autogel 120mg at a 3-weekly interval, after disease progression on standard 4-weekly doses, were retrospectively identified. Clinicopathologic and treatment response data were collected. Progression-free survival (PFS - dose escalation to radiographic progression or death) was estimated with the Kaplan - Meier method. Factors associated with PFS were identified with the Cox proportional-hazards model. Results Inclusion criteria were fulfilled by 105 patients. Octreotide LAR was administered to 60 (57%) and lanreotide Autogel to 45 (43%). Indications for dose escalation were breakthrough carcinoid symptoms (58%), radiographic progression (35%) and/or increasing biomarkers (11%). Diarrheal and/or flushing symptomatic improvement was identified in 37/67 (55%) and 30/55 cases (55%) with available data, respectively. Disease control rate (radiographic partial response or stable disease) was achieved in 53 patients (50%). Median PFS was 25.0 months (95% CI 16.9 - 33.1). Patients with radiographic progression less then 12 months from 4-weekly SSA initiation had worse PFS after dose escalation (7.0 vs. 17.0 months, p = 0.002). In multivariate analysis, pancreatic NETs, Ki-67?5% and multiple extrahepatic metastases were independently associated with inferior PFS. Conclusions Above-label doses of SSAs may offer a considerable prolongation in PFS and could be utilized as a bridge to other more toxic treatments. Patients with small bowel/colorectal primaries, Ki-67 less then 5% and absence of/limited extrahepatic metastases are more likely to benefit from this approach.Background Cyst compression of renal tubules plays a role in the progression of autosomal dominant polycystic kidney disease (ADPKD) and may induce expression of kidney injury molecule-1 (KIM-1). Whether urinary KIM-1 indexed for creatinine (uKIM-1/Cr) is a prognostic marker of disease progression in ADPKD is unknown.In this secondary analysis of a prospective cohort study, we sought to determine whether patients with high as opposed to low uKIM-1/CR at baseline had greater rates of eGFR loss and height-adjusted total kidney volume (HtTKV) increase. Methods Baseline uKIM-1/Cr values were obtained from 754 participants in Halt Progression of Polycystic Kidney Disease (HALT-PKD) studies A (early ADPKD) and B (late ADPKD). The predictor was uKIM-1/Cr, which was dichotomized by a median value of 0.2417 pg/g, and the primary outcomes were measured longitudinally over time. Mixed-effects linear models were used in the analysis to calculate the annual slope of change in eGFR and HtTKV. Results Patients with high uKIM-1/Cr (above the median) had an annual decline in eGFR that was 0.